Interventions for the prevention of recurrent erysipelas and cellulitis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Dalal, Adam ^a,b   Eskin Schwartz, Marina ^a,b   Mimouni, Daniel ^a,b   Ray, Sujoy ^c   Days, Walford ^d   Hodak, Emmilia ^a,b   Leibovici, Leonard ^a   Paul, Mical ^e  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e Division of Infectious Diseases   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZATHINE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; SODIUM SELENITE; ANTIINFECTIVE AGENT; BENZATHINE PENICILLIN; PENICILLIN V; SELENIUM;

ABDOMINAL PAIN; ADVERSE OUTCOME; AGE DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CELLULITIS; DIARRHEA; ERYSIPELAS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; INCIDENCE; INJECTION SITE REACTION; MORBIDITY; MORTALITY RATE; NAUSEA; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; ARM; LEG DERMATOSES; META ANALYSIS; MIDDLE AGED; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ARM; CELLULITIS; ERYSIPELAS; ERYTHROMYCIN; HOSPITALIZATION; HUMANS; LEG DERMATOSES; MIDDLE AGED; PENICILLIN G BENZATHINE; PENICILLIN V; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; SELENIUM;

EID: 85021089465     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009758.pub2     Document Type: Review

References (157)

1. Chakroun M, Ben-Romdhane F, Battikh R, Souki A, Bouzouaia N. Benzathine penicillin prophylaxis in recurrent erysipelas [Intérêt de la benzathine pénicilline dans la prévention des récidives d'érysipèle]. Médecine et Maladies Infectieuses 1994;24(10):894-7. [CENTRAL: CN-00169390; EMBASE: 1994338740]5774834
2. Kasseroller R. Prophylaxis of erysipelas in secondary lymphedema with selenium [Erysipelprophylaxe beim sekundären Lymphödem mit Selen]. Der Allgemeinarzt 1996;18(3):244-7. 5774836
3. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Research 1998;18(3C):2227-30. [CENTRAL: CN-00153878; EMBASE: 1998283262]5774837
4. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. Journal of Infection 1991;22(1):37-40. [CENTRAL: CN-00073794; PUBMED: 2002231]5774839
5. Sjöblom AC, Eriksson B, Jorup-Rönström C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993;21(6):390-3. [CENTRAL: CN-00099842; PUBMED: 8132369]5774841
6. Centre of Evidence Based Dermatology. Prophylactic Antibiotics for the Treatment of Cellulitis at Home (PATCH). www.nottingham.ac.uk/research/groups/cebd/projects/patch.aspx (accessed 6th June 2017). 5774843
7. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II Trials. PLoS One 2014;9(2):e82694. [DOI: 10.1371/journal.pone.0082694; PUBMED: 24551029]5774844
8. Thomas KS, UK Dermatology Clinical Trials Network's PATCH study group. Studying a disease with no home--lessons in trial recruitment from the PATCH II study. Trials 2010;11(22):1-5. [DOI: 10.1186/1745-6215-11-22; PUBMED: 20196846]5774845
9. UK Dermatology Clinical Trials Network's PATCH Trial Team, Thomas K, Crook A, Foster K, Mason J, Chalmers J, Bourke J, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial. British Journal of Dermatology 2012;166(1):169-78. [CENTRAL: CN-00836571; PUBMED: 21910701]5774846
10. Centre of Evidence Based Dermatology. Prophylactic Antibiotics for the Treatment of Cellulitis at Home (PATCH). www.nottingham.ac.uk/research/groups/cebd/projects/patch.aspx (accessed 6th June 2017). 5774848
11. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II Trials. PLoS One 2014;9(2):e82694. [DOI: 10.1371/journal.pone.0082694; PUBMED: 24551029]5774849
12. Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, et al. Penicillin to prevent recurrent leg cellulitis. New England Journal of Medicine 2013;368(18):1695-703. [CENTRAL: CN-00859316; PUBMED: 23635049]5774850
13. Williams HC, Crook AM, Mason JM, UK Dermatology Clinical Trials Network's PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis. New England Journal of Medicine 2013;369(9):881-2. [DOI: 10.1056/NEJMc1307321; PUBMED: 23984744]5774851
14. Duvanel T, Harms M, Merot Y, Saurat JH. Les récidives d'érysipèle et leur prévention par la benzathine-penicilline. Annales de Dermatologie et de Vénéréologie 1986;113:174-6. 5774853
15. Ferrieri P, Dajani AS, Wannamaker LW. Benzathine penicillin in the prophylaxis of streptococcal skin infections: a pilot study. Journal of Pediatrics 1973;83(4):572-7. [CENTRAL: CN-00009022; PUBMED: 4581016]5774855
16. Fritz SA, Camins BC, Eisenstein KA, Fritz JM, Epplin EK, Burnham CA, et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infection Control and Hospital Epidemiology 2011;32(9):872-80. [CENTRAL: CN-00804495; PUBMED: 21828967]5774857
17. Haustein UF, Biella U, Tausch I, Knöll H. Treatment of chronic recurrent erysipelas with streptococcal vaccine [Die behandlung des chronisch rezidivierenden erysipels mit Streptokokkenvakzine]. Hautarzt 1989;40(4):215-21. [PUBMED: 2659550]5774859
18. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988;260(18):2682-5. [CENTRAL: CN-00056409; PUBMED: 3184334]5774861
19. Maddox JS, Ware JC, Dillon HC. The natural history of streptococcal skin infection: prevention with topical antibiotics. Journal of the American Academy of Dermatology 1985;13(2 Pt 1):207-12. [CENTRAL: CN-00039750; PUBMED: 2995463]5774863
20. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Archives of Internal Medicine 1996;156(10):1109-12. [CENTRAL: CN-00124903; PUBMED: 8638999]5774865
21. Wang JH, Liu YC, Cheng DL, Yen MY, Chen YS, Wang JH, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clinical Infectious Diseases 1997;25(3):685-9. [CENTRAL: CN-00143909; PUBMED: 9314462]5774867
22. Ratnikova LI. Effectiveness of bemitil in recurrent erysipelas Klinicheskaia Meditsina 1991;69(7):89-90. [CENTRAL: CN-00079309; EMBASE: 1942990]5774869
23. Addiss DG, Michel MC, Michelus A, Radday J, Billhimer W, Louis-Charles J, et al. Evaluation of antibacterial soap in the management of lymphoedema in Leogane, Haiti. Transactions of the Royal Society of Tropical Medicine and Hygiene 2011;105(1):58-60.
24. Australasian Lymphology Association (ALA). Consensus Guideline: Management of Cellulitis in Lymphoedema. www.lymphoedema.org.au/public/7/files/ALA%20CELLULITIS%20IN%20LYMPHOEDEMA%202015.pdf (accessed May 2017).
25. Allard P, Stücker M, Von Kobyletzki G, el Gammal S, Altmeyer P. Cyclical intravenous antibiosis as an effective therapy concept in chronic recurrent erysipelas [Zyklische intravenöse Antibiose als effizientes Therapiekonzept des chronisch-rezidivierenden Erysipels]. Hautarzt 1999;50(1):34-8. [PUBMED: 10068929]
26. Arakaki RY, Strazzula L, Woo E, Kroshinsky D. The impact of dermatology consultation on diagnostic accuracy and antibiotic use among patients with suspected cellulitis seen at outpatient internal medicine offices: a randomized clinical trial. JAMA Dermatology 2014;150(10):1056-61. [PUBMED: 25143179]
27. Arasaratnam R. Penicillin to prevent recurrent leg cellulitis. New England Journal of Medicine 2013;369(9):881. [DOI: 10.1056/NEJMc1307321#SA2; PUBMED: 23984746]
28. Arsenault K, Rielly L, Wise H. Effects of complete decongestive therapy on the incidence rate of hospitalization for the management of recurrent cellulitis in adults with lymphedema. Rehabilitation Oncology 2011;29(3):14-20. [EMBASE: 2011656495]
29. Arumugam D, Atherton JJ, Martin PT. A lethal injection?. Lancet 2012;379(9814):492. [PUBMED: 22305227]
30. Babb RR, Spittell JA Jr, Martin WJ, Schirger A. Prophylaxis of recurrent lymphangitis complicating lymphedema. JAMA 1966;195(10):871-3. [PUBMED: 12608187]
31. Baddour LM. Cellulitis syndromes: an update. International Journal of Antimicrobial Agents 2000;14(2):113-6. [PUBMED: 10720800]
32. Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. Epidemiology and comorbidity of erysipelas in primary care. Dermatology 2007;215(2):118-22. [PUBMED: 17684373]
33. Bernard P, Toty L, Mounier M, Denis F, Bonnetblanc JM. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Archives of Dermatology 1987;123(4):468-70. [PUBMED: 3827278]
34. Biosyn Selenase®. Selenium as a beacon of hope [Selen als Hoffnungsträge]. www.biosyn.de/innovation/selen-als-hoffnungstraeger (accessed January 2015).
35. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. New England Journal of Medicine 1996;334(4):240-5. [PUBMED: 8532002]
36. Bitnun S. Prophylactic antibiotics in recurrent erysipelas. Lancet 1985;1(8424):345. [PUBMED: 2857399]
37. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, Gunnarsson GB, Rikardsdottir H, Kristjansson M, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clinical Infectious Diseases 2005;41(10):1416-22. [PUBMED: 16231251]
38. British Lymphology Society (BLS). Consensus Document on the Management of Cellulitis in Lymphoedema. Revised Cellulitis Guidelines 2016. www.lymphoedema.org/images/pdf/CellulitisConsensus.pdf (accessed May 2017).
39. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clinical Microbiology Reviews 2001;14(2):244-69. [PUBMED: 11292638]
40. Brook I, Frazier EH. Clinical features and aerobic and anaerobic microbiological characteristics of cellulitis. Archives of Surgery 1995;130(7):786-92. [PUBMED: 7611872]
41. Brorson H. Liposuction gives complete reduction of chronic large arm lymphedema after breast cancer. Acta Oncologica 2000;39(3):407-20. [PUBMED: 10987239]
42. Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. Etiology of cellulitis and clinical prediction of streptococcal disease: a prospective study. Open Forum Infectious Diseases 2015;31(1):ofv181. [PUBMED: 26734653]
43. Campisi CC, Ryan M, Boccardo F, Campisi C. A single-site technique of multiple lymphatic-venous anastomoses for the treatment of peripheral lymphedema: long-term clinical outcome. Journal of Reconstructive Microsurgery 2016;32(1):42-9. [PUBMED: 26029991]
44. Carratala J, Roson B, Fernandez-Sabe N, Shaw E, Del Rio O, Rivera A, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. European Journal of Clinical Microbiology & Infectious Diseases 2003;22(3):151-7. [PUBMED: 12649712]
45. Chaniotakis I, Gartzonika CG, Gaitanis G, Levidiotou-Stefanou S, Bassukas ID. Causality evaluation of bacterial species isolated from patients with community-acquired lower leg cellulitis. Journal of the European Academy of Dermatology and Venereology 2016;30(9):1583-9. [PUBMED: 27400752]
46. Chen HM, Li YL, Liu YM, Liu CE, Cheng YR, Chen CH, et al. The experience of intramuscular benzathine penicillin for prophylaxis of recurrent cellulitis: A cohort study. Journal of Microbiology, Immunology, & Infection 2015;S1684-1182(15):00831-2. [PUBMED: 26475200]
47. Chira S, Miller LG. Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiology and Infection 2010;138(3):313-7. [PUBMED: 19646308]
48. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. New England Journal of Medicine 2014;370(23):2180-90. [PUBMED: 24897083]
49. Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. Journal of The Royal Society of Medicine 1998;91(12):634-7.
50. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. British Journal of Dermatology 2006;155(5):947-50. [PUBMED: 17034523 ]
51. CREST. Clinical Resource Efficiency Support Team (CREST). Guidelines on the management of cellulitis in adults. www.acutemed.co.uk/docs/Cellulitis%20guidelines, %20CREST, %2005.pdf 2005 (accessed 6th June 2017).
52. Crisp JG, Takhar SS, Moran GJ, Krishnadasan A, Dowd SE, Finegold SM, et al. Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis. Clinical Infectious Diseases 2015;61(11):1679-87. [PUBMED: 26240200]
53. Damstra RJ, Van Steensel MA, Boomsma JH, Nelemans P, Veraart JC. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. British Journal of Dermatology 2008;158(6):1210-5. [PUBMED: 18363756]
54. Damstra RJ, Voesten HG, Van Schelven WD, Van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Research & Treatment 2009;113(2):199-206. [PUBMED: 18270813]
55. David CV, Chira S, Eells SJ, Ladrigan M, Papier A, Miller LG, et al. Diagnostic accuracy in patients admitted to hospitals with cellulitis. Dermatology Online Journal 2011;17(3):1. [PUBMED: 21426867]
56. De Godoy JM, De Godoy MF, Valente A, Camacho EL, Paiva EV. Lymphoscintigraphic evaluation in patients after erysipelas. Lymphology 2000;33(4):177-80. [PUBMED: 11191659]
57. Didem K, Ufuk YS, Serdar S, Zümre A. The comparison of two different physiotherapy methods in treatment of lymphedema after breast surgery. Breast Cancer Research & Treatment 2005;93(1):49-54. [PUBMED: 16184458]
58. Draijer LW, Koning S, Wielink G, Boukes FS, Goudswaard AN. Summary of the practice guideline 'Bacterial skin infections' (first revision) from the Dutch College of General Practitioners [Samenvatting van de standaard 'Bacteriële huidinfecties'(eerste herziening) van het Nederlands Huisartsen Genootschap]. Nederlands Tijdschrift voor Geneeskunde 2008;152(29):1619-25. [PUBMED: 18998269]
59. Finnish Medical Society Duodecim and the Finnish Dermatological Society. Bacterial skin infections (online). Current care guideline. October 1999 [updated November 2010] [Ihon bakteeri-infektiot]. www.kaypahoito.fi (accessed 11 February 2016):1-3 (accessed December 2013).
60. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999;318(7198):1591-4. [PUBMED: 10364117]
61. Durand M, Wistaff R, Lelorier J. Penicillin to prevent recurrent leg cellulitis. New England Journal of Medicine 2013;369(9):880. [DOI: 10.1056/NEJMc1307321#SA1; PUBMED: 23984745]
62. Duvanel T, Merot Y, Harms M, Saurat JH. Prophylactic antibiotics in erysipelas. Lancet 1985;1(8442):1401. [PUBMED: 2861358]
63. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Archives of Internal Medicine 1989;149(2):293-6. [PUBMED: 2644902]
64. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563]
65. Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, et al. Cellulitis incidence in a defined population. Epidemiology & Infection 2006;134(2):293-9. [PUBMED: 16490133]
66. Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clinical Infectious Diseases 1996;23(5):1091-8. [PUBMED: 8922808]
67. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy 2003;52(Suppl 1):i3-17. [PUBMED: 14662806]
68. Esposito S, Bassetti M, Borre S, Bouza E, Dryden M, Fantoni M, et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. Journal of Chemotherapy 2011;23(5):251-62. [PUBMED: 22005055]
69. Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, et al. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD003475.pub2]
70. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clinical & Experimental Dermatology 1994;19(3):210-6. [PUBMED: 8033378]
71. Garau J, Blasi F, Medina J, McBride K, Ostermann H, REACH study group. Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infectious Diseases 2015;15(78):1-9. [PUBMED: 25879713]
72. Gerber MA. Antibiotic resistance in group A streptococci. Pediatric Clinics of North America 1995;42(3):539-51. [PUBMED: 7761140]
73. Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. Journal of the European Academy of Dermatology and Venereology 2006;20(7):834-9. [PUBMED: 16898907]
74. Goscinski G, Tano E, Thulin P, Norrby-Teglund A, Sjölin J. Release of SpeA from Streptococcus pyogenes after exposure to penicillin: dependency on dose and inhibition by clindamycin. Scandinavian Journal of Infectious Diseases 2006;38(11-12):983-7. [PUBMED: 17148065]
75. Granzow JW, Soderberg JM, Kaji AH, Dauphine C. Review of current surgical treatments for lymphedema. Annals of Surgical Oncology 2014;21(4):1195-201. [PUBMED: 24558061]
76. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279(5):365-70. [PUBMED: 9459469]
77. Halpern J, Holder R, Langford NJ. Ethnicity and other risk factors for acute lower limb cellulitis: a UK-based prospective case-control study. British Journal of Dermatology 2008;158(6):1288-92. [PUBMED: 18341662]
78. Harris SR, Hugi MR, Olivotto IA, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ: Canadian Medical Association Journal 2001;164(2):191-9. [PUBMED: 11332311]
79. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
80. Hook EW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Archives of Internal Medicine 1986;146(2):295-7. [PUBMED: 3947189]
81. Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clinical Infectious Diseases 1998;26(6):1341-5. [PUBMED: 9636860]
82. International Lymphoedema Framework (ILF). Best Practice for the Management of Lymphoedema. International consensus 2006. http://www.lympho.org/portfolio/best-practice-for-the-management-of-lymphoedema/ (accessed 6th June 2017):1-60.
83. Inghammar M, Rasmussen M, Linder A. Recurrent erysipelas-risk factors and clinical presentation. BMC Infectious Diseases 2014 May;14:270. [DOI: 10.1186/1471-2334-14-270; PUBMED: 24884840]
84. International Society of Lymphology (ISL). The diagnosis and treatment of peripheral lymphedema: Consensus document. Lymphology 2013;46(1):1-11. [PUBMED: 23930436]
85. Israeli Ministry of Health. Safety warning over the use of intramuscular Benzathine benzylpenicillin February 2015 www.health.gov.il/newsandevents/recall_drugs/doclib1/benzathine_benzylpenicillin.pdf (accessed August 2015).
86. Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010;89(4):217-26. [PUBMED: 20616661]
87. Jorup-Rönström C. Epidemiological, bacteriological and complicating features of erysipelas. Scandinavian Journal of Infectious Diseases 1986;18(6):519-24. [PUBMED: 3810046]
88. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987;15(2):105-6. [PUBMED: 3110071]
89. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6. [PUBMED: 11440947 ]
90. Karimkhani C, Boyers LN, Margolis DJ, Naghavi M, Hay RJ, Williams HC, et al. Comparing cutaneous research funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease results. PLoS One 2014;9(7):e102122. [PUBMED: 25003335]
91. Karimkhani C, Boyers LN, Prescott L, Welch V, Delamere FM, Nasser M, et al. Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. JAMA Dermatology 2014;150(9):945. [PUBMED: 24807687]
92. Karppelin M, Siljander T, Vuopio-Varkila J, Kere J, Huhtala H, Vuento R, et al. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clinical Microbiology & Infection 2010;16(6):729-34. [PUBMED: 19694769]
93. Karppelin M, Siljander T, Huhtala H, Aroma A, Vuopio J, Hannula-Jouppi K, et al. Recurrent cellulitis with benzathine penicillin prophylaxis associated with diabetes and psoriasis. European Journal of Clinical Microbiology & Infectious Diseases 2013;32(3):369-72. [PUBMED: 23007460]
94. Karppelin M, Siljander T, Aittoniemi J, Hurme M, Huttunen R, Huhtala H, et al. Predictors of recurrent cellulitis in five years. Clinical risk factors and the role of PTX3 and CRP. Journal of Infection 2015;70(5):467-73. [DOI: 10.1016/j.jinf.2014.11.002; PUBMED: 25447714]
95. Kasseroller R. Erysipelprophylaxe beim sekundären Lymphödem mit Selen. Der Allgemeinartzt 1996;3:244-7.
96. Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD004299.pub2]
97. Ko DS, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Archives of Surgery 1998;133(4):452-8. [PUBMED: 9565129]
98. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004;292(6):709-15. [PUBMED: 15304468]
99. Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagnostic Microbiology & Infectious Disease 1999;34(4):325-7. [PUBMED: 10459485]
100. Kouyos RD, Metcalf CJ, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al. The path of least resistance: aggressive or moderate treatment?. Proceedings. Biological Sciences / the Royal Society 2014;281(1794):1-8. [PUBMED: 25253451]
101. Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosopical Transactions of the Royal Society B 2015;370(1670):1-9. [DOI: 10.1098/rstb.2014.0306; PUBMED: 25918446]
102. Lazzarini L, Conti E, Tositti G, De Lalla F. Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. Journal of Infection 2005;51(5):383-9. [PUBMED: 16321649]
103. Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. British Journal of Dermatology 2011;164(6):1326-8. [PUBMED: 21564054]
104. Lewis SD, Peter GS, Gomez-Marin O, Bisno AL. Risk factors for recurrent lower extremity cellulitis in a U.S. Veterans Medical Center population. American Journal of the Medical Sciences 2006;332(6):304-7. [PUBMED: 17170620]
105. Lum GR. Cellulitis among active duty service members, US Armed Forces, 1998-2001. Medical Surveillance Monthly Report (MSMR) 2002;8:6-9.
106. Mallon E, Powell S, Mortimer P, Ryan TJ. Evidence for altered cell-mediated immunity in postmastectomy lymphoedema. British Journal of Dermatology 1997;137(6):928-33. [PUBMED: 9470909]
107. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7. Vol. 1, Philadelphia: Churchill Livingstone, 2010.
108. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II Trials. PLoS One 2014;9(2):e82694. [DOI: 10.1371/journal.pone.0082694; PUBMED: 24551029]
109. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969;207(6):1115-9. [PUBMED: 5818242 ]
110. McNamara DR, Tleyjeh IM, Berbari EF, Lahr BD, Martinez J, Mirzoyev SA, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Archives of Internal Medicine 2007;167(7):709-15. [PUBMED: 17420430]
111. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clinical Infectious Diseases 2005;41(8):1114-22. [PUBMED: 16163629]
112. Mertz KR, Baddour LM, Bell JL, Gwin JL. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. Clinical Infectious Diseases 1998;26(2):481-6. [PUBMED: 9502474]
113. Miller SR, Mondry T, Reed JS, Findley A, Johnstone PA. Delayed cellulitis associated with conservative therapy for breast cancer. Journal of Surgical Oncology 1998;67(4):242-5. [PUBMED: 9579371]
114. Mokni M, Dupuy A, Denguezli M, Dhaoui R, Bouassida S, Amri M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006;212(2):108-12. [PUBMED: 16484815]
115. Moreland NJ, Waddington CS, Williamson DA, Sriskandan S, Smeesters PR, Proft T, et al. Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop. Vaccine 2014;32(30):3713-20. [PUBMED: 24837510]
116. Morris AD. Cellulitis and erysipelas. Clinical Evidence 2008;01(1708):1-8. [PUBMED: 19450336]
117. Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. Journal of Clinical Investigation 2014;124(3):915-21. [PUBMED: 24590276]
118. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy 2001;47(Suppl 1):17-23. [PUBMED: 11096185]
119. National Institute for Health and Care Excellence (NICE). Cellulitis - acute 2005. //cks.nice.org.uk/cellulitis-acute#!topicsummary (accessed March 2015).
120. Oh CC, Ko HC, Lee HY, Safdar N, Maki DG, Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. Journal of Infection 2014;69(1):26-34. [DOI: 10.1016/j.jinf.2014.02.011; PUBMED: 24576824]
121. Ostermann H, Blasi F, Medina J, Pascual E, McBride K, Garau J, REACH study group. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study. Journal of Medical Economics 2014;17(10):719-29. [PUBMED: 24983206]
122. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PUBMED: 9921604]
123. Pauszek ME. Prophylaxis for recurrent cellulitis complicating venous and lymphatic insufficiency. Indiana Medicine 1991;84(4):252-3. [PUBMED: 2037773]
124. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. Journal Der Deutschen Dermatologischen Gesellschaft 2004;2(2):89-95. [PUBMED: 16279242]
125. Pierce RP, Daugird AJ. Recurrent leg cellulitis: pathogenesis, treatment, and prevention. Journal of the American Board of Family Medicine 1992;5(1):85-7. [PUBMED: 1561927]
126. Quirke M, Ayoub F, McCabe A, Boland F, Smith B, O'Sullivan R, et al. Risk factors for non-purulent leg cellulitis: a systematic review and meta-analysis. British Journal of Dermatology 2016 Nov 18 [Epub ahead of print]. [DOI: 10.1111/bjd.15186]
127. Raff AB, Kroshinsky D. Cellulitis: a review. JAMA 2016;316(3):325-37. [PUBMED: 27434444]
128. Read AF, Day T, Huijben S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2011;108(Suppl 2):10871-7. [PUBMED: 21690376 ]
129. Roldan YB, Mata-Essayag S, Hartung C. Erysipelas and tinea pedis. Mycoses 2000;43(5):181-3. [PUBMED: 10948816]
130. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004;209(4):301-7. [PUBMED: 15539893]
131. Sawai J, Hasegawa T, Kamimura T, Okamoto A, Ohmori D, Nosaka N, et al. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrobial Agents & Chemotherapy 2007;51(2):461-7. [DOI: 10.1128/AAC.00539-06; PUBMED: 17101685]
132. Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendation. The GRADE Working Group, 2013. Available from:http://gdt.guidelinedevelopment.org/app/handbook/handbook.html.
133. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clinical Infectious Diseases 1996;23(5):1162-4. [PUBMED: 8922818]
134. French Society of Dermatology [Société Française de Dermatologie]. Management of erysipelas and necrotizing fasciitis [Erysipèle et fasciite nécrosante:prise en charge]. Annales de Dermatologie et de Vénéréologie 2000;127(12):1118-37. [PUBMED: 11173699]
135. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G. A double-blind, placebo-controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis. Annals of Tropical Medicine & Parasitology 1999;93(4):367-77. [PUBMED: 10656038]
136. Siljander T, Karppelin M, Vahakuopus S, Syrjanen J, Toropainen M, Kere J, et al. Acute bacterial, nonnecrotizing cellulitis in Finland: microbiological findings. Clinical Infectious Diseases 2008;46(6):855-61. [PUBMED: 18260753]
137. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. American Journal of Medicine 1992;93(5):543-8. [PUBMED: 1364813]
138. Soo JK, Bicanic TA, Heenan S, Mortimer PS. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. British Journal of Dermatology 2008;158(6):1350-3. [PUBMED: 18241266]
139. Stalbow J. Preventing cellulitis in older people with persistent lower limb oedema. British Journal of Nursing 2004;13(12):725-32. [PUBMED: 15284636]
140. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases 2005;41(10):1373-406. [PUBMED: 16231249]
141. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2014;59(2):e10-52. [DOI: 10.1093/cid/ciu444; PUBMED: 24973422]
142. Stoberl C, Partsch H. Erysipelas and lymphedema--egg or hen?. Zeitschrift für Hautkrankheiten 1987;62(1):56-62. [PUBMED: 3577282]
143. Strazzula L, Cotliar J, Fox LP, Hughey L, Shinkai K, Gee SN, et al. Inpatient dermatology consultation aids diagnosis of cellulitis among hospitalized patients: A multi-institutional analysis. Journal of the American Academy of Dermatology 2015;73(1):70-5. [PUBMED: 26089048]
144. Swartz MN. Clinical practice. Cellulitis. New England Journal of Medicine 2004;350(9):904-12. [PUBMED: 14985488]
145. Szolnoky G, Dobozy A, Kemény L. Towards an effective management of chronic lymphedema. Clinics in Dermatology 2014 Sep-Oct;32(5):685-91. [PUBMED: 25160111]
146. Tay EY, Fook-Chong S, Oh CC, Thirumoorthy T, Pang SM, Lee HY. Cellulitis Recurrence Score: A tool for predicting recurrence of lower limb cellulitis. Journal of the American Academy of Dermatology 2015;72(1):140-5. [DOI: 10.1016/j.jaad.2014.08.043; PUBMED: 25443627]
147. Thind P. Prophylactic antibiotics in recurrent erysipelas. Lancet 1985;1(8435):986. [PUBMED: 2859444]
148. Thomas KS, UK Dermatology Clinical Trials Network's PATCH study group. Studying a disease with no home--lessons in trial recruitment from the PATCH II study. Trials 2010;11(2):1-5. [DOI: 10.1186/1745-6215-11-22; PUBMED: 20196846]
149. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
150. Van Zuuren EJ, Fedorowicz Z, Alper B, Mitsuma SF. Penicillin to prevent recurrent leg cellulitis: a critical appraisal. British Journal of Dermatology 2014;171(6):1300-3. [DOI: 10.1111/bjd.13461; PUBMED: 25523263]
151. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infectious Diseases 2005;5(8):501-13. [PUBMED: 16048719]
152. Weng QY, Raff AB, Cohen JM, Gunasekera N, Okhovat JP, Vedak P, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatology 2016 Nov 2 [Epub ahead of print]. [DOI: 10.1001/jamadermatol.2016.3816; PUBMED: 27806170]
153. World Health Organization. Benzathine penicillin: three fatal reports following mega unit injections. Drug Information Bulletin 2000;4(2):1.
154. Woo PC, Lum PN, Wong SS, Cheng VC, Yuen KY. Cellulitis complicating lymphoedema. European Journal of Clinical Microbiology & Infectious Diseases 2000;19(4):294-7. [PUBMED: 10834819]
155. Yamamoto T, Koshima I. Supermicrosurgical anastomosis of superficial lymphatic vessel to deep lymphatic vessel for a patient with cellulitis-induced chronic localized leg lymphedema. Microsurgery 2015;35(1):68-71. [PUBMED: 25197031]
156. Young JR, Dewolfe VG. Recurrent lymphangitis of the leg associated with dermatophytosis. Report of 25 consecutive cases. Cleveland Clinic quarterly 1960;27:19-24. [PUBMED: 13846637]
157. Dalal A, Eskin-Shwartz M, Mimouni D, Ray S, Days W, Hodak E, et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD009758]